1. Home
  2. ELVN vs PLSE Comparison

ELVN vs PLSE Comparison

Compare ELVN & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • PLSE
  • Stock Information
  • Founded
  • ELVN 2016
  • PLSE 2014
  • Country
  • ELVN United States
  • PLSE United States
  • Employees
  • ELVN N/A
  • PLSE N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • PLSE Medical/Dental Instruments
  • Sector
  • ELVN Health Care
  • PLSE Health Care
  • Exchange
  • ELVN Nasdaq
  • PLSE Nasdaq
  • Market Cap
  • ELVN 1.1B
  • PLSE 1.0B
  • IPO Year
  • ELVN 2020
  • PLSE 2016
  • Fundamental
  • Price
  • ELVN $27.53
  • PLSE $15.98
  • Analyst Decision
  • ELVN Strong Buy
  • PLSE
  • Analyst Count
  • ELVN 3
  • PLSE 0
  • Target Price
  • ELVN $34.33
  • PLSE N/A
  • AVG Volume (30 Days)
  • ELVN 309.7K
  • PLSE 162.1K
  • Earning Date
  • ELVN 11-07-2024
  • PLSE 11-11-2024
  • Dividend Yield
  • ELVN N/A
  • PLSE N/A
  • EPS Growth
  • ELVN N/A
  • PLSE N/A
  • EPS
  • ELVN N/A
  • PLSE N/A
  • Revenue
  • ELVN N/A
  • PLSE N/A
  • Revenue This Year
  • ELVN N/A
  • PLSE N/A
  • Revenue Next Year
  • ELVN N/A
  • PLSE N/A
  • P/E Ratio
  • ELVN N/A
  • PLSE N/A
  • Revenue Growth
  • ELVN N/A
  • PLSE N/A
  • 52 Week Low
  • ELVN $9.80
  • PLSE $3.78
  • 52 Week High
  • ELVN $27.67
  • PLSE $22.69
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 73.14
  • PLSE 39.51
  • Support Level
  • ELVN $24.60
  • PLSE $15.90
  • Resistance Level
  • ELVN $27.55
  • PLSE $18.72
  • Average True Range (ATR)
  • ELVN 1.41
  • PLSE 1.14
  • MACD
  • ELVN 0.40
  • PLSE -0.27
  • Stochastic Oscillator
  • ELVN 98.56
  • PLSE 1.48

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Share on Social Networks: